161 related articles for article (PubMed ID: 30276959)
21. Benefit of downsizing hepatocellular carcinoma in a liver transplant population.
Jang JW; You CR; Kim CW; Bae SH; Yoon SK; Yoo YK; Kim DG; Choi JY
Aliment Pharmacol Ther; 2010 Feb; 31(3):415-23. PubMed ID: 19821808
[TBL] [Abstract][Full Text] [Related]
22. Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list.
Kardashian AA; Dodge JL; Roberts J; Brandman D
Liver Int; 2018 Mar; 38(3):553-563. PubMed ID: 28727287
[TBL] [Abstract][Full Text] [Related]
23. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
[TBL] [Abstract][Full Text] [Related]
24. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
[TBL] [Abstract][Full Text] [Related]
25. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
Guerrini GP; Pinelli D; Marini E; Corno V; Guizzetti M; Zambelli M; Aluffi A; Lincini L; Fagiuoli S; Lucianetti A; Colledan M
Prog Transplant; 2018 Mar; 28(1):63-69. PubMed ID: 29251164
[TBL] [Abstract][Full Text] [Related]
26. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.
Pelletier SJ; Fu S; Thyagarajan V; Romero-Marrero C; Batheja MJ; Punch JD; Magee JC; Lok AS; Fontana RJ; Marrero JA
Liver Transpl; 2009 Aug; 15(8):859-68. PubMed ID: 19642139
[TBL] [Abstract][Full Text] [Related]
27. Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC.
Fuks D; Cauchy F; Fusco G; Paradis V; Durand F; Belghiti J
J Hepatol; 2014 Sep; 61(3):589-93. PubMed ID: 24818985
[TBL] [Abstract][Full Text] [Related]
28. Performance of pre-transplant criteria in prediction of hepatocellular carcinoma progression and waitlist dropout.
Piñero F; Thompson M; Boin I; Chagas A; Quiñonez E; Bermúdez C; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Perales SR; Maccali C; Vergara Sandoval R; McCormack L; Varón A; Marciano S; Mattera J; Carrilho F; Silva M
Liver Int; 2022 Aug; 42(8):1879-1890. PubMed ID: 35304813
[TBL] [Abstract][Full Text] [Related]
29. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
[TBL] [Abstract][Full Text] [Related]
30. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.
Cucchetti A; Cescon M; Bigonzi E; Piscaglia F; Golfieri R; Ercolani G; Cristina Morelli M; Ravaioli M; Daniele Pinna A
Liver Transpl; 2011 Nov; 17(11):1344-54. PubMed ID: 21837731
[TBL] [Abstract][Full Text] [Related]
31. Time of Dropout From the Liver Transplant List in Patients With Hepatocellular Carcinoma: Clinical Behavior According to Tumor Characteristics and Severity of Liver Disease.
Salvalaggio PR; Felga GE; Guardia BD; Almeida MD; Pandullo FL; Matielo CE; Evangelista A; Curvelo L; Rocco RA; Alves JA; Meirelles RF; Filho SP; de Rezende MB; Pedroso PT; Diaz LG; Rusi MB; Viveiros MM; Neves DB
Transplant Proc; 2016 Sep; 48(7):2319-2322. PubMed ID: 27742288
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients.
Sayiner M; Stepanova M; De Avila L; Golabi P; Racila A; Younossi ZM
Dig Dis Sci; 2020 Feb; 65(2):416-422. PubMed ID: 31451982
[TBL] [Abstract][Full Text] [Related]
33. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
34. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
[TBL] [Abstract][Full Text] [Related]
35. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular carcinoma progression during bridging before liver transplantation.
Renner P; Da Silva T; Schnitzbauer AA; Verloh N; Schlitt HJ; Geissler EK
BJS Open; 2021 Mar; 5(2):. PubMed ID: 33839747
[TBL] [Abstract][Full Text] [Related]
37. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
38. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation.
Orci LA; Berney T; Majno PE; Lacotte S; Oldani G; Morel P; Mentha G; Toso C
Br J Surg; 2015 Sep; 102(10):1250-7. PubMed ID: 26098966
[TBL] [Abstract][Full Text] [Related]
39. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.
Merani S; Majno P; Kneteman NM; Berney T; Morel P; Mentha G; Toso C
J Hepatol; 2011 Oct; 55(4):814-9. PubMed ID: 21334400
[TBL] [Abstract][Full Text] [Related]
40. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
Huang AC; Dodge JL; Yao FY; Mehta N
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1581-1589. PubMed ID: 36038129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
